Retatrutide is a triple-receptor agonist of glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors. In this phase 3, randomized, double-blind trial, we assign...

GLM-5.3 can autonomously build end-to-end cyber exploits, but unlike other frontier models, it was released without meaningful safeguards to limit misuse.